Feb 23 |
Citius Pharmaceuticals files for $250M mixed securities shelf
|
Feb 23 |
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
|
Feb 14 |
Citius Pharmaceuticals GAAP EPS of -$0.06
|
Feb 14 |
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
|
Feb 14 |
Citius resubmits marketing application for lymphoma therapy
|
Feb 14 |
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
Jan 23 |
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
|
Jan 2 |
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
|
Jan 2 |
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
|
Dec 3 |
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
|